Inclusion of artificial intelligence in essential medicine policy analysis

Introduction The National List of Essential Medicines (NLEM) serves as a cornerstone of India’s pharmaceutical policy, ensuring the availability and accessibility of key therapeutic agents based on public health relevance, efficacy, safety, and cost-effectiveness.[1] The 2022 revision of the NLEM brought significant changes, including the inclusion of drugs for human immunodeficiency virus, tuberculosis, and COVID-19.[2] However, the consolidation of certain pharmacological categories sparked debate, highlighting the complexity of essential medicine selection. In recent years, artificial intelligence (AI) has revolutionized the healthcare systems globally. AI technologies such as machine learning, natural language processing (NLP), and predictive analytics are now employed in diagnostics, personalized medicine, public health surveillance, and clinical decision support.[3-5] This manuscript proposes that similar tools are leveraged in the formulation and refinement of essential medicine policies. Applications of Artificial Intelligence in Essential Medicine Policy Predictive analytics: AI can process vast datasets to forecast disease patterns and anticipate medication requirements. This real-time adaptability enables proactive policy decisions, ensuring that the NLEM remains responsive to emerging health threats[6] Personalized dosage and drug interaction alerts: AI-driven platforms can support optimal dosage decisions and alert policymakers to potential drug interactions, improving the clinical relevance and safety profile of listed medicines Stakeholder feedback synthesis: Incorporating feedback from diverse stakeholders is central to NLEM updates. NLP algorithms can analyze large volumes of qualitative feedback from healthcare professionals, nongovernmental organizations, and patient groups to extract common concerns and priorities Cost-effectiveness analysis: AI tools can integrate clinical and economic data to model the cost–benefit profiles of drugs, aiding decisions on the inclusion of newer or high-cost medications Antimicrobial resistance surveillance: AI can consolidate resistance data from hospitals and laboratories to predict resistance trends, enabling timely updates to antimicrobial listings[7] Drug classification optimization: AI clustering algorithms can evaluate drug attributes and therapeutic categories, supporting rational classification and sectioning in the NLEM. Global Case Studies In the United States, the Food and Drug Administration uses AI to enhance pharmacovigilance and streamline drug approval processes[3] The UK’s National Health Service employs AI-driven predictive analytics for resource planning and drug procurement[4] China has developed AI platforms to monitor and respond to antimicrobial resistance.[7] Challenges and Ethical Considerations Data interoperability: AI’s effectiveness is contingent on access to clean, integrated, and standardized datasets. Fragmented healthcare data in India present a major barrier to AI adoption[5] Algorithmic bias: Bias in AI models can exacerbate existing healthcare disparities. Ensuring representative datasets and continuous monitoring is critical Explainable AI: Policymakers and healthcare providers must understand AI-generated insights. The development and deployment of interpretable models are essential[4] Regulatory and ethical oversight: AI use must comply with ethical principles, including data privacy, consent, and accountability. Rigorous validation protocols are necessary for policy-grade applications[5] Capacity building: Cross-sector collaboration and professional training are required to foster AI literacy among policymakers and healthcare stakeholders.[1] Conclusion Integrating AI into the essential medicine policymaking process holds a significant promise for enhancing the relevance, responsiveness, and equity of national drug lists. While challenges remain, a structured and ethically guided approach can enable India to lead in leveraging AI for public health policy. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.